{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Neoplasm&page=84",
    "query": {
      "condition": "Recurrent Neoplasm",
      "page": 84
    },
    "page_size": 10
  },
  "pagination": {
    "page": 84,
    "page_size": 10,
    "total_count": 9123,
    "total_pages": 913,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Neoplasm&page=85&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Neoplasm&page=83&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T01:23:31.103Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01588522",
      "title": "Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chemotherapy-Induced Alopecia"
      ],
      "interventions": [
        {
          "name": "Compound 31543 Calcitriol 5 μg/mL",
          "type": "DRUG"
        },
        {
          "name": "Compound 31543 Calcitriol 10 μg/mL",
          "type": "DRUG"
        },
        {
          "name": "Compound 31543 Calcitriol 20 μg/mL",
          "type": "DRUG"
        },
        {
          "name": "Compound 31543 Calcitriol 40 μg/mL",
          "type": "DRUG"
        },
        {
          "name": "Compound 31543 Calcitriol 60 ug/mL",
          "type": "DRUG"
        },
        {
          "name": "Compound 31543 Calcitriol 80 μg/mL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BPGbio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2012-09-17",
      "completion_date": "2017-02-16",
      "has_results": true,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-11-11T01:23:31.103Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01588522"
    },
    {
      "nct_id": "NCT00684229",
      "title": "Regional Anesthesia in Colon Rectal Surgery",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Colon Cancer"
      ],
      "interventions": [
        {
          "name": "Regional anesthesia and analgesia",
          "type": "PROCEDURE"
        },
        {
          "name": "general anesthesia followed by opioid analgesia",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2007-12",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2016-09-15",
      "last_synced_at": "2026-11-11T01:23:31.103Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00684229"
    },
    {
      "nct_id": "NCT00003945",
      "title": "Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 400,
      "start_date": "1999-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-05-27",
      "last_synced_at": "2026-11-11T01:23:31.103Z",
      "location_count": 8,
      "location_summary": "Indianapolis, Indiana • Des Moines, Iowa • Papillion, Nebraska + 3 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Papillion",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003945"
    },
    {
      "nct_id": "NCT00053365",
      "title": "Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Peritoneal Cavity Cancer",
        "Recurrent Ovarian Epithelial Cancer"
      ],
      "interventions": [
        {
          "name": "irofulven",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 85 Years · Female only"
      },
      "enrollment_count": 61,
      "start_date": "2003-06",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2019-07-24",
      "last_synced_at": "2026-11-11T01:23:31.103Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00053365"
    },
    {
      "nct_id": "NCT05798507",
      "title": "Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Avutometinib",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Defactinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2023-07-28",
      "completion_date": "2027-12-03",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-11-11T01:23:31.103Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05798507"
    },
    {
      "nct_id": "NCT05645107",
      "title": "A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypogammaglobulinemia",
        "Bacterial Infections",
        "B-cell Chronic Lymphocytic Leukemia",
        "Multiple Myleoma",
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Xembify",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 386,
      "start_date": "2022-12-26",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-11-11T01:23:31.103Z",
      "location_count": 9,
      "location_summary": "Bullhead City, Arizona • Huntington Park, California • St. Petersburg, Florida + 6 more",
      "locations": [
        {
          "city": "Bullhead City",
          "state": "Arizona"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05645107"
    },
    {
      "nct_id": "NCT02164461",
      "title": "Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Effects of Immunotherapy",
        "Metastatic/Recurrent Cervical Cancer",
        "Cervical Adenocarcinoma",
        "Cervical Adenosquamous Cell Carcinoma",
        "Cervical Squamous Cell Carcinoma",
        "Cervical Small Cell Carcinoma",
        "Stage III Cervical Cancer",
        "Stage IVA Cervical Cancer",
        "Stage IVB Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "Axalimogene filolisbac",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Advaxis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2015-03-04",
      "completion_date": "2017-03-08",
      "has_results": true,
      "last_update_posted_date": "2024-05-20",
      "last_synced_at": "2026-11-11T01:23:31.103Z",
      "location_count": 2,
      "location_summary": "Augusta, Georgia • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02164461"
    },
    {
      "nct_id": "NCT00003454",
      "title": "Antineoplaston Therapy in Treating Women With Stage IV Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Antineoplaston therapy (Atengenal + Astugenal)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Burzynski Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 99 Years · Female only"
      },
      "enrollment_count": 19,
      "start_date": "1996-03-18",
      "completion_date": "2002-12-28",
      "has_results": false,
      "last_update_posted_date": "2017-09-28",
      "last_synced_at": "2026-11-11T01:23:31.103Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003454"
    },
    {
      "nct_id": "NCT01325805",
      "title": "Efficacy of a Structured Weight Loss Program in Overweight Women With a History of Recurrent Pregnancy Loss",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obese",
        "Overweight",
        "Miscarriage",
        "Recurrent Pregnancy Loss"
      ],
      "interventions": [
        {
          "name": "Structured Weight Loss Program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Routine Weight Loss Counseling",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 39 Years · Female only"
      },
      "enrollment_count": 7,
      "start_date": "2010-12",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2022-01-03",
      "last_synced_at": "2026-11-11T01:23:31.103Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01325805"
    },
    {
      "nct_id": "NCT01093222",
      "title": "Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Extrahepatic Bile Duct Adenocarcinoma",
        "Gallbladder Adenocarcinoma",
        "Gallbladder Adenocarcinoma With Squamous Metaplasia",
        "Hilar Cholangiocarcinoma",
        "Recurrent Extrahepatic Bile Duct Carcinoma",
        "Recurrent Gallbladder Carcinoma",
        "Undifferentiated Gallbladder Carcinoma",
        "Unresectable Extrahepatic Bile Duct Carcinoma",
        "Unresectable Gallbladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "Erlotinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2010-04",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2015-06-30",
      "last_synced_at": "2026-11-11T01:23:31.103Z",
      "location_count": 141,
      "location_summary": "Tucson, Arizona • Loma Linda, California • Los Angeles, California + 95 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Marysville",
          "state": "California"
        },
        {
          "city": "Novato",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01093222"
    }
  ]
}